119 related articles for article (PubMed ID: 12209590)
1. TP53 mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: association with risk factors and tumor characteristics.
Simão TA; Ribeiro FS; Amorim LM; Albano RM; Andrada-Serpa MJ; Cardoso LE; Mendonça GA; de Moura-Gallo CV
Int J Cancer; 2002 Sep; 101(1):69-73. PubMed ID: 12209590
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
3. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
4. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
6. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
7. TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis.
Neves Filho EH; Cordeiro DE; Vieira AP; Rabenhorst SH
Pathobiology; 2012; 79(6):323-8. PubMed ID: 22688387
[TBL] [Abstract][Full Text] [Related]
8. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
9. An intronic variant in the TP53 gene in a Brazilian woman with breast cancer.
Lacerda LL; Serrano SV; Mathes A; Rey JA; Bello MJ; Casartelli C
Cancer Genet Cytogenet; 2005 Jul; 160(2):160-3. PubMed ID: 15993272
[TBL] [Abstract][Full Text] [Related]
10. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
11. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
12. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
[TBL] [Abstract][Full Text] [Related]
13. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
[TBL] [Abstract][Full Text] [Related]
14. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
[TBL] [Abstract][Full Text] [Related]
15. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
16. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
18. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in TP53 and risk of breast cancer in a population-based case control study.
Sprague BL; Trentham-Dietz A; Garcia-Closas M; Newcomb PA; Titus-Ernstoff L; Hampton JM; Chanock SJ; Haines JL; Egan KM
Carcinogenesis; 2007 Aug; 28(8):1680-6. PubMed ID: 17449902
[TBL] [Abstract][Full Text] [Related]
20. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
